Piper Sandler analyst Jason Bednar reiterated a Buy rating on Alpha Tau Medical Ltd (DRTS – Research Report) today and set a price target of $12.00. The company’s shares closed yesterday at $3.25.
According to TipRanks, Bednar is an analyst with an average return of -6.7% and a 36.65% success rate. Bednar covers the Healthcare sector, focusing on stocks such as Merit Medical Systems, NovoCure, and Align Tech.
Currently, the analyst consensus on Alpha Tau Medical Ltd is a Moderate Buy with an average price target of $10.50, representing a 223.08% upside. In a report released on August 18, H.C. Wainwright also reiterated a Buy rating on the stock with a $9.00 price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $9.69 and a one-year low of $2.75. Currently, Alpha Tau Medical Ltd has an average volume of 79.78K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alpha Tau is an Israel-based medical device company focusing on the research, development, and potential commercialization of the Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) for the treatment of solid tumors.
Read More on DRTS:
- Alpha Tau Medical Announces Second Quarter 2023 Financial Results and Provides Corporate Update
- Alpha Tau Medical to Participate in September Investor Conferences
- Is DRTS a Buy, Before Earnings?
- Alpha Tau’s Alpha DaRT shows safety and efficacy in multiple trials
- Alpha Tau Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha DaRT
